In 2019 regulators and independent testers began reporting measurable levels of N-nitrosodimethylamine (NDMA) in some ranitidine products. NDMA is a nitrosamine impurity classified as a probable human carcinogen by national and international agencies, and the pattern of NDMA formation in ranitidine raised two practical problems: (1) NDMA levels in some ranitidine samples were above interim acceptable intake limits established by regulators, and (2) NDMA in ranitidine was observed to increase with time and with elevated storage temperatures, making it difficult to guarantee safety across a product's shelf life. citeturn2search0turn0search1
The U.S. Food and Drug Administration (FDA) issued a sequence of updates through late 2019 and early 2020. After company-level voluntary recalls and expanded testing, the FDA requested that manufacturers withdraw all ranitidine products from the U.S. market on April 1, 2020 — instructing companies to remove both prescription and over-the-counter ranitidine (including branded Zantac and multiple generics) because NDMA levels could exceed acceptable limits during normal storage. The FDA's market-withdrawal request is the regulatory anchor for the recalls and product suspensions that followed. citeturn0search0
Important technical points for consumers and clinicians:
The pattern across manufacturer notices shows:
| Brand / Manufacturer | Typical product (example) | First public recall notice | Notes / outcome |
|---|---:|---|---|
| Sanofi (Zantac OTC) | Zantac OTC 75 mg, 150 mg | Sept–Oct 2019 (consumer notices) | Sanofi issued OTC recall communications and later pulled product following FDA guidance. {{FDA_COUNT}}. citeturn0search5 |
| Glenmark | Ranitidine 150 mg / 300 mg | Dec 2019 (voluntary recall) | Glenmark recalled all unexpired lots and ceased distribution in the U.S.; FDA posted company recall notice. {{RECALL_COUNT}}. citeturn3search0 |
| Apotex | Ranitidine OTC 75 mg & 150 mg | Sept 2019 (precautionary recall) | Widely publicized early generic recall; retailer-labeled products (Wal-Zan®, etc.) were involved. citeturn3search1 |
| Dr. Reddy's | Various ranitidine products | Late 2019 (recall announcements) | Company confirmed voluntary nationwide recall for lots with certain expiry dates. citeturn3search3 |
| Others (Amneal, Aurobindo, Sandoz, Northwind etc.) | Multiple formulations | Late 2019–Feb 2020 | Multiple manufacturer-level lot recalls before April 2020 FDA market removal request. citeturn3search15 |
This timeline condenses the main regulatory events and testing signals that led to market withdrawal and later developments such as reformulation and re-approval attempts.
Below is a sample summary table you can populate from RecallTracker feeds using the variables provided. We include columns for reported recall items, brand-level counts, and a simple timeline anchor. Replace the tokens with your live counts (e.g., from the RecallTracker database or FDA recall RSS feeds) for publication.
| Metric | Value |
|---|---:|
| Distinct ranitidine recall notices captured (all sources) | {{RECALL_COUNT}} |
| FDA recall / press entries specifically on ranitidine / NDMA | {{FDA_COUNT}} |
| Manufacturer-level recall notices (distinct manufacturers) | {{CPSC_COUNT}} |
| Recalls logged in {{RECALLS_2025}} | {{RECALLS_2025}} |
| Recalls so far in {{RECALLS_2026_YTD}} (year-to-date) | {{RECALLS_2026_YTD}} |
Notes:
NDMA is a nitrosamine impurity with established carcinogenicity in animals and mechanistic reasons to consider it hazardous to humans at sufficient lifetime exposure levels. Regulatory thresholds (for example the FDA's interim acceptable intake of 96 nanograms per day for ranitidine) are conservative benchmarks used to limit avoidable lifetime cancer risk from medication impurities. These thresholds are context-sensitive and factor in conservative safety margins. citeturn2search0turn3search2
Important context when interpreting risk:
If you are concerned about past ranitidine use, talk to your clinician. Medical decisions should balance individual risk factors, duration and dose of past ranitidine use, and alternative treatment options. RecallTracker does not provide medical advice; use these materials to inform a clinician conversation.
Actionable checklist (printer-friendly)
Following the recalls, ranitidine-related litigation consolidated in multiple venues. Plaintiffs alleged exposure to NDMA increased cancer risk; defendants responded with challenges to causation and exposure quantification. A range of case management actions, MDLs, and settlement negotiations have occurred since 2020. The specifics of any litigation outcome vary by case and by firm; if you believe you qualify for a legal claim consult a licensed attorney. (This is informational, not legal advice.) citeturn3search15turn3search18
We cross-link relevant longer-form content on our site for readers who want background or technical details:
Ranitidine products were requested to be withdrawn from the U.S. market by the FDA on April 1, 2020, because NDMA levels could increase during storage and exceed acceptable intake bounds. A reformulated ranitidine product received FDA approval on Nov 24, 2025 after manufacturing and packaging changes intended to address NDMA formation. For current availability check FDA product listings and our brand recall lookup lookup. citeturn0search0turn1view0
Short answer: no. Detection of NDMA in a medication lot indicates a potential increase in lifetime cancer risk from chronic exposure, but it does not mean every exposed person will develop cancer. Risk depends on dose, duration of exposure, and individual factors. If you're concerned about past ranitidine use, speak with your clinician. Public health guidance focuses on preventing avoidable exposures. citeturn2search0turn0search1
Record the lot number and expiration date, then either scan the barcode in the RecallTracker app barcode scanner or visit our brand recall lookup brand recall lookup. Confirm the lot against manufacturer or FDA recall notices; follow the recall return or disposal instructions if it matches. citeturn3search2
Many ranitidine-related lawsuits were consolidated into multidistrict litigation (MDL) and other coordinated proceedings. Outcomes have varied: some cases remain active, some have moved toward settlement negotiations, and others involve ongoing discovery. Consult legal counsel if you believe you have an actionable claim; RecallTracker only summarizes public filings and recall notices. citeturn3search15turn3search18
Yes. Clinically established alternatives include other H2 blockers (like famotidine) and proton pump inhibitors (PPIs) depending on the clinical situation. Discuss options with your clinician, especially if you were using ranitidine for chronic management. If you switch medications, keep the packaging or prescription records and monitor for manufacturer updates via brand recall lookup and recall statistics.
Zantac (ranitidine) is a clear case study in how an impurity — NDMA — and its production dynamics can change a widely used medicine's risk profile. Regulatory action (notably the FDA's April 1, 2020 market withdrawal request) reflected precautionary public-health practice because NDMA levels in ranitidine were variable and could rise during storage. Since then, manufacturers and regulators have worked on reformulation and improved manufacturing controls; the FDA approved a reformulated ranitidine product on Nov 24, 2025 that includes specific storage and handling directions. citeturn0search0turn1view0
If you have ranitidine at home, follow the checklist above: stop use, record lot information, scan it with the app at barcode scanner, check brand recall lookup, and talk to your clinician if you have concerns. For broader trends and to export recall data for your own analysis, visit recall statistics. Consider RecallTracker Premium for prioritized alerts and CSV exports; details are at RecallTracker Premium.
Related reading on RecallTracker:
When evaluating zantac products, understanding the difference between brand-name and generic formulations helps contextualize recall risk. Both are subject to the same FDA manufacturing standards, but recall patterns differ based on production scale, facility practices, and raw material sourcing.
| Factor | Brand-Name Products | Generic Products |
|---|---|---|
| Manufacturing oversight | Single primary manufacturer | Multiple manufacturers globally |
| Recall frequency | Lower absolute count | Higher count due to more producers |
| Common recall reasons | Packaging, labeling | Contamination, potency variation |
| Consumer notification speed | Direct-to-patient programs | Pharmacy-level notification |
Consumers should check lot numbers on every prescription fill. The lot number connects your specific bottle to the production batch, making it possible to verify whether your supply is affected by a recall. Pharmacies are required to remove recalled lots from their inventory, but products already dispensed remain the consumer's responsibility to check.
For proactive monitoring, scan medication barcodes at /scan, search by drug name at /brands, and review FDA action trends at /statistics. RecallTracker Premium at /pricing sends immediate alerts when your medication category has a new recall.
Check the lot number on your medication packaging and scan the barcode at /scan. You can also search by brand or generic name at /brands. The FDA publishes enforcement reports that are indexed in RecallTracker's database of {{FDA_COUNT}} FDA actions.
Do not stop taking prescribed medication without consulting your healthcare provider first. Contact your pharmacist to discuss alternatives and check if your specific lot number is affected. Use /brands to verify the recall scope and follow the manufacturer's instructions for returns or replacements.
Common reasons include contamination with impurities (such as NDMA or other nitrosamines), incorrect dosage or potency, mislabeling, failed dissolution testing, and microbial contamination. These issues are tracked in {{RECALL_COUNT}} total recalls across all agencies. Check /statistics for drug recall trends.
The FDA conducts inspections of manufacturing facilities, reviews adverse event reports, and runs laboratory testing programs. When problems are found, the agency works with manufacturers on voluntary recalls or issues mandatory actions. Monitor FDA activity at /statistics and set up alerts at /pricing for your specific medications.
Most recall notices include instructions for returns or refunds through the manufacturer or your pharmacy. Keep your receipt and the original packaging as proof of purchase. Check the specific recall details at /brands for the manufacturer's contact information and refund process.